Last reviewed · How we verify
DP — Competitive Intelligence Brief
marketed
Betalactam antibiotic
transpeptidase
Infectious diseases
Small molecule
Live · refreshed every 30 min
Target snapshot
DP (DP) — Medecins Sans Frontieres, Netherlands. DP is a medication used to treat certain types of infections caused by bacteria.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| DP TARGET | DP | Medecins Sans Frontieres, Netherlands | marketed | Betalactam antibiotic | transpeptidase | |
| Aspirin | acetylsalicylic acid | Bayer AG | marketed | NSAID, Antiplatelet agent | Gamma-glutamyltranspeptidase 1, Nicotinate phosphoribosyltransferase, Acid-sensing ion channel 3 | 1899-03-06 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Betalactam antibiotic class)
- Medecins Sans Frontieres, Netherlands · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- DP CI watch — RSS
- DP CI watch — Atom
- DP CI watch — JSON
- DP alone — RSS
- Whole Betalactam antibiotic class — RSS
Cite this brief
Drug Landscape (2026). DP — Competitive Intelligence Brief. https://druglandscape.com/ci/dp. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab